These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 28027999)

  • 1. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
    Fan XM; Zhang J; Niu SH; Li KX; Song CZ
    Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical cytoreduction for recurrent epithelial ovarian cancer.
    Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
    Chi DS; McCaughty K; Diaz JP; Huh J; Schwabenbauer S; Hummer AJ; Venkatraman ES; Aghajanian C; Sonoda Y; Abu-Rustum NR; Barakat RR
    Cancer; 2006 May; 106(9):1933-9. PubMed ID: 16572412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer.
    Frederick PJ; Ramirez PT; McQuinn L; Milam MR; Weber DM; Coleman RL; Gershenson DM; Landen CN
    Int J Gynecol Cancer; 2011 Jul; 21(5):831-6. PubMed ID: 21613957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
    Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
    Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
    Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
    Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary cytoreductive surgery in the management of platinum-sensitive recurrent epithelial ovarian cancer.
    Park JY; Eom JM; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
    J Surg Oncol; 2010 Apr; 101(5):418-24. PubMed ID: 20082350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
    Li YF; Li MD; Liu FY; Liu JH; Li JD
    Ai Zheng; 2003 Nov; 22(11):1193-6. PubMed ID: 14613651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
    Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
    J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
    Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
    Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
    Falcone F; Scambia G; Benedetti Panici P; Signorelli M; Cormio G; Giorda G; Bogliolo S; Marinaccio M; Ghezzi F; Rabaiotti E; Breda E; Casella G; Fanfani F; Di Donato V; Leone Roberti Maggiore U; Greggi S
    Gynecol Oncol; 2017 Oct; 147(1):66-72. PubMed ID: 28716306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical observation of partial pancreatectomy as part of primary cytoreductive surgery in advanced epithelial ovarian cancer].
    Xiang LB; Tu YX; He TC; Pei X; Shen XX; Yang WT; Wu XH; Yang HJ
    Zhonghua Fu Chan Ke Za Zhi; 2016 May; 51(5):361-5. PubMed ID: 27256444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.
    Zang RY; Zhang ZY; Li ZT; Chen J; Tang MQ; Liu Q; Cai SM
    J Surg Oncol; 2000 Sep; 75(1):24-30. PubMed ID: 11025458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer.
    Katsnelson M; Hwang WT; Tahirovic E; Rubin SC; Tanyi JL
    J Obstet Gynaecol; 2018 Apr; 38(3):395-401. PubMed ID: 29385863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of prognosis and associated factors in multiple recurrent epithelial ovarian cancer with three times or more cytoreductive surgeries].
    Zou RY; Yuan L; Chen M; Yao LQ
    Zhonghua Fu Chan Ke Za Zhi; 2023 Mar; 58(3):198-206. PubMed ID: 36935197
    [No Abstract]   [Full Text] [Related]  

  • 17. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
    Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
    Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of outcomes of secondary debulking surgery for recurrent epithelial ovarian cancer with favorable prognostic factors.
    Nasu K; Kai K; Hirakawa T; Nishida M; Matsumoto H; Kawano Y; Narahara H
    J Obstet Gynaecol Res; 2014 Mar; 40(3):791-6. PubMed ID: 24245582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
    Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
    Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anesthetic selection and disease-free survival following optimal primary cytoreductive surgery for stage III epithelial ovarian cancer.
    Elias KM; Kang S; Liu X; Horowitz NS; Berkowitz RS; Frendl G
    Ann Surg Oncol; 2015 Apr; 22(4):1341-8. PubMed ID: 25287437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.